Thus, the team at Agios Pharmaceuticals in the US demonstrated the mechanism by which MAT2A inhibition induces DNA damage and mitotic defects in MTAP-deleted cancers using RNA sequencing and proteomics. The gene discussed is MAT2A; the disease is cancer.